Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.61 |
| ▸ | PLAU | P00749 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14812371 | 0.91 | PLA2G2A (0.57) | PLA2G2APLAUKMT2AMEN1KDM4E | |
| SCHEMBL1938779 | 0.84 | PLA2G2A (0.54) | PLA2G2APLAUKMT2AMEN1TAAR1 | |
| SCHEMBL4368371 | 0.84 | PARP10 (0.46) | PLA2G2APLAUKMT2AMEN1TAAR1 | |
| SCHEMBL2958348 | 0.84 | PLA2G2A (0.61) | PLA2G2APLAUKMT2AMEN1PKM | |
| SCHEMBL14536663 | 0.82 | L3MBTL1 (0.48) | PLA2G2APLAUKMT2AMEN1TAAR1 | |
| SCHEMBL1572959 | 0.82 | KMT2A (0.71) | KMT2ATAAR1PLA2G4B | |
| SCHEMBL1543649 | 0.82 | PLA2G2A (0.62) | PLA2G2APLAUKMT2AMEN1PKM | |
| SCHEMBL28529167 | 0.81 | PLA2G2A (0.67) | PLA2G2APLAUKMT2AMEN1PKM | |
| Hydrochloric Acid SCHEMBL25378558 | 0.80 | KMT2A (0.69) | KMT2ATAAR1PLA2G4B | |
| SCHEMBL15148310 | 0.80 | PLA2G2A (0.53) | PLA2G2APLAUKMT2AMEN1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | claimed |
| WO-2024118635-A2 | THERMOSTABLE BINDING SCAFFOLDS | NECTAGEN, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240174730-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024010810-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-4297796-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230364251-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230302108-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | Elicio Therapeutics, Inc. | 2023-09-28 | — | — | US | disclosed |
| WO-2015035102-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-1853605-B1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING SPA (IT) | 2014-09-10 | — | — | EP | disclosed |
| US-20110172126-A1 | LIBRARIES OF PEPTIDE CONJUGATES AND METHODS FOR MAKING THEM | XENOME LTD (AU) | 2011-07-14 | — | — | US | disclosed |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | BRACCO IMAGING S.P.A. (IT) | 2008-12-25 | — | — | US | disclosed |
| US-20080312344-A1 | DENDRIMERS MULTIVALENTLY SUBSTITUTED WITH ACTIVE GROUPS | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | disclosed |
| EP-1896079-A1 | DENDRIMERS MULTIVALENTLY SUBSTITUTED WITH ACTIVE GROUPS | Universiteit Utrecht Holding B.V. (NL) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006135233-A1 | DENDRIMERS MULTIVALENTLY SUBSTITUTED WITH ACTIVE GROUPS | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2006-12-21 | — | — | WO | disclosed |
| EP-1733742-A1 | Dendrimers multivalently substituted with active groups | Universiteit Utrecht Holding B.V. (NL) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | PLA2G2A 2159/4885PLAU 836/4885KMT2A 4104/4885 |
| US-20080312344-A1 | DENDRIMERS MULTIVALENTLY SUBSTITUTED WITH ACTIVE GROUPS | DNPEP, DDOST, IAPP | PLA2G2A 3084/4885PLAU 344/4885KMT2A 4182/4885 |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | MMP3, MMP7, MMP9 | PLA2G2A 2090/4885PLAU 83/4885KMT2A 1798/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | PLA2G2A 2159/4885PLAU 836/4885KMT2A 4104/4885 |
| US-20230364251-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | DNPEP, NPEPPS, DHFR | PLA2G2A 3978/4885PLAU 2669/4885KMT2A 2734/4885 |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | ITGA2B, ITGB2, ITGB1 | PLA2G2A 3310/4885PLAU 481/4885KMT2A 3272/4885 |
| US-20240174730-A1 | VARIANT FC DOMAINS AND USES THEREOF | FCGR3B, FCGRT, FCGR2A | PLA2G2A 1288/4885PLAU 2130/4885KMT2A 321/4885 |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | PLA2G2A 2159/4885PLAU 836/4885KMT2A 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.